BeOne Medicines (ONC) Competitors $299.01 -2.12 (-0.70%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ONC vs. SNY, GSK, TAK, ARGX, BNTX, SMMT, INSM, TEVA, GMAB, and MRNAShould you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. BeOne Medicines vs. Its Competitors Sanofi GSK Takeda Pharmaceutical argenex BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Is ONC or SNY more profitable? Sanofi has a net margin of 21.47% compared to BeOne Medicines' net margin of -9.40%. Sanofi's return on equity of 18.85% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-9.40% -7.55% -4.42% Sanofi 21.47%18.85%10.85% Do analysts recommend ONC or SNY? BeOne Medicines presently has a consensus target price of $327.56, suggesting a potential upside of 9.55%. Sanofi has a consensus target price of $62.00, suggesting a potential upside of 32.62%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Sanofi 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 3 Strong Buy rating(s) 3.13 Do institutionals and insiders hold more shares of ONC or SNY? 48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, ONC or SNY? Sanofi has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B8.60-$644.79M-$3.72-80.38Sanofi$44.46B2.58$6.02B$2.8016.70 Does the media refer more to ONC or SNY? In the previous week, Sanofi had 31 more articles in the media than BeOne Medicines. MarketBeat recorded 44 mentions for Sanofi and 13 mentions for BeOne Medicines. Sanofi's average media sentiment score of 0.74 beat BeOne Medicines' score of 0.41 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 21 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, ONC or SNY? BeOne Medicines has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. SummarySanofi beats BeOne Medicines on 13 of the 17 factors compared between the two stocks. Get BeOne Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricBeOne MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.77B$2.50B$5.52B$9.37BDividend YieldN/A1.80%4.74%4.13%P/E Ratio-80.389.0928.9923.78Price / Sales8.60687.56440.5195.88Price / CashN/A155.1435.0756.59Price / Book8.774.838.255.54Net Income-$644.79M$31.62M$3.25B$259.97M7 Day Performance2.59%-5.28%-3.75%-4.67%1 Month Performance21.80%3.12%2.99%3.29%1 Year PerformanceN/A-2.00%25.34%17.92% BeOne Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCBeOne Medicines0.7294 of 5 stars$299.01-0.7%$327.56+9.5%N/A$32.77B$3.81B-80.3811,000News CoverageUpcoming EarningsInsider TradeGap UpSNYSanofi4.3449 of 5 stars$50.37+0.5%$62.00+23.1%-11.9%$123.53B$45.17B17.9982,878Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGSKGSK2.4959 of 5 stars$37.95-0.7%$37.38-1.5%-7.1%$78.27B$40.10B19.5668,629Trending NewsEarnings ReportDividend CutAnalyst UpgradeTAKTakeda Pharmaceutical2.4053 of 5 stars$14.47-1.3%N/A+0.6%$46.65B$30.09B65.7547,455News CoverageGap UpHigh Trading VolumeARGXargenex3.0624 of 5 stars$591.99+0.0%$728.06+23.0%+34.8%$36.21B$2.25B36.521,599Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBNTXBioNTech2.7626 of 5 stars$115.31+0.6%$136.58+18.4%+30.9%$27.54B$2.75B-33.916,772News CoverageUpcoming EarningsGap DownSMMTSummit Therapeutics2.8921 of 5 stars$28.67+4.0%$34.67+20.9%+159.9%$20.48B$700K-84.32110Upcoming EarningsINSMInsmed3.6932 of 5 stars$103.95+0.4%$109.20+5.1%+51.4%$19.64B$363.71M-17.471,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9739 of 5 stars$16.53+1.2%$24.71+49.5%-9.5%$18.73B$16.54B-14.3836,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.636 of 5 stars$23.40-1.0%$37.80+61.5%-22.9%$15.01B$3.12B13.302,682News CoverageUpcoming EarningsShort Interest ↑MRNAModerna4.3919 of 5 stars$34.15+0.4%$46.11+35.0%-68.1%$13.15B$3.14B-3.915,800Trending NewsEarnings ReportAnalyst ForecastOptions Volume Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives BNTX Alternatives SMMT Alternatives INSM Alternatives TEVA Alternatives GMAB Alternatives MRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONC) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts